市場調查報告書
商品編碼
1423062
2024-2032 年旅遊疫苗市場報告(按成分、疾病和地區)Travel Vaccines Market Report by Composition, Disease, and Region 2024-2032 |
2023年全球旅行疫苗市場規模達到40億美元。展望未來, IMARC Group預計到2032年市場規模將達到94億美元,2024-2032年複合年成長率(CAGR)為9.6%。由於對異國情調和不走尋常路的旅行體驗的需求不斷成長、政府作為公共衛生計劃的一部分向公民提供免費旅行疫苗的舉措以及不斷變化的疾病模式和新出現的威脅,該市場正在經歷穩定成長。
市場成長與規模:市場正在強勁成長,這可歸因於國際旅行活動的增加。此外,大眾對旅行相關疾病的認知不斷提高,也推動了市場的成長。
技術進步:疫苗開發方面的創新,例如引入更方便、更有效的配方,確保為旅行者提供更好的保護。
產業應用:旅行疫苗對於休閒和商務旅客都至關重要,因為它們可以預防各種疾病。
地理趨勢:北美由於高度重視旅行期間的健康和安全而引領市場。然而,在多樣化的目的地和大量國際遊客的推動下,歐洲正在成為一個快速成長的市場。
競爭格局:市場主要參與者積極參與策略舉措。他們正在投資研發(R&D)活動,以擴大其疫苗組合,解決新出現的與旅行相關的健康風險,並提高疫苗的現有功效。
挑戰與機會:雖然市場面臨疫苗猶豫和監管障礙等挑戰,但它也遇到了擴大疫苗可及性和為特定地區量身定做疫苗解決方案的機會。
未來展望:隨著疫苗生產方面持續的研發(R&D)活動,旅行疫苗市場的未來看起來充滿希望。此外,採用數位健康解決方案進行旅行前諮詢預計將推動市場的成長。
國際旅行不斷增加
世界各地大眾國際旅行的增加正在支持市場的成長。隨著全球化和旅行便利性的不斷增強,世界各地感染傳染病的風險正在上升。旅行者正在冒險前往醫療保健標準和疾病流行率各不相同的目的地,因此接種疫苗成為至關重要的預防措施。休閒旅行、商務旅行和國際學生出國留學的成長進一步推動了這一趨勢。此外,對異國情調和人跡罕至的旅行體驗的渴望正在引導人們探索具有獨特健康風險的地區,這強調了對專門疫苗的需求。人們對旅行時健康預防措施的認知不斷增強,凸顯了疫苗對國際旅客的重要性,這提供了良好的市場前景。
政府措施和法規
政府措施和法規在推動市場方面發揮關鍵作用。許多國家正在認知到維護公共衛生和防止疾病透過國際旅行傳播的重要性。因此,一些國家的管理機構正在實施有關旅行疫苗接種的嚴格法規和建議。這些法規通常要求進出其邊境的旅行者接種某些疫苗,特別是對於具有已知疾病風險的目的地。世界衛生組織 (WHO) 的《國際衛生條例》(IHR) 要求前往某些國家的旅客提供黃熱病疫苗接種證明。此外,作為公共衛生計劃的一部分,一些政府為其公民提供補貼或免費旅行疫苗接種。這些法規和措施不僅為旅行者提出了法律要求,也提高了人們對旅行疫苗必要性的認知,從而推動了市場需求。
全球疾病爆發和流行病
全球疾病爆發和流行病對推動市場產生深遠影響。這些事件鼓舞了旅客和政府,並凸顯了與國際旅行相關的潛在健康風險。為了應對此類疫情,對能夠預防某些地區流行的特定傳染病的疫苗的需求不斷增加。疾病爆發和流行病導致疫苗的開發和分發,以減輕病毒的傳播並促進安全旅行。旅行者越來越意識到需要接種疫苗來保護自己和他人,導致更多人採用旅行疫苗。各國政府和國際衛生組織也強調疫苗作為預防和控制疫情的關鍵工具的重要性,並鼓勵旅客在踏上旅程之前接種疫苗。
不斷變化的疾病模式和新出現的威脅
疾病模式的動態性質和新傳染病威脅的出現正在加強市場的成長。傳染病並不是一成不變的,它們會進化、變異並傳播到新的地區。這種不斷變化的情況需要持續的疫苗研發 (R&D) 活動來對抗不斷變化的病原體。近年來,寨卡病毒和伊波拉病毒等疾病日益成為旅客的重大擔憂,促使特定疫苗的開發來應對這些威脅。這種對疾病模式變化的認知,以及獲取資訊的便利性,正在鼓勵人們在踏上旅程之前透過疫苗接種尋求保護。
The global travel vaccines market size reached US$ 4.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 9.4 Billion by 2032, exhibiting a growth rate (CAGR) of 9.6% during 2024-2032. The market is experiencing steady growth driven by the escalating demand for exotic and off-the-beaten-path travel experiences, government initiatives to provide free travel vaccinations to their citizens as part of public health programs, and changing disease patterns and emerging threats.
Market Growth and Size: The market is witnessing strong growth, which can be attributed to increasing international travel activities. In addition, the rising awareness among the masses about travel-related diseases is bolstering the market growth.
Technological Advancements: Innovations in vaccine development, such as the introduction of more convenient and effective formulations, is ensuring better protection for travelers.
Industry Applications: Travel vaccines are crucial for both leisure and business travelers, as they offer protection against various diseases.
Geographical Trends: North America leads the market, on account of its strong emphasis on health and safety during travel. However, Europe is emerging as a fast-growing market, driven by its diverse range of destinations and a large number of international travelers.
Competitive Landscape: Key players in the market are actively engaged in strategic initiatives. They are investing in research and development (R&D) activities to expand their vaccine portfolios, addressing emerging travel-related health risks, and enhancing existing efficacy of vaccines.
Challenges and Opportunities: While the market faces challenges, such as vaccine hesitancy and regulatory hurdles, it also encounters opportunities in expanding vaccine accessibility and tailored vaccine solutions for specific regions.
Future Outlook: The future of the travel vaccines market looks promising, with ongoing research and development (R&D) activities in vaccine production. Moreover, the adoption of digital health solutions for pre-travel consultations is expected to propel the growth of the market.
Rising international travel
The increasing international travel among the masses around the world is supporting the growth of the market. As globalization and accessibility to travel are growing, the risk of exposure to infectious diseases in various parts of the world is rising. Travelers are venturing to destinations with varying healthcare standards and disease prevalence, making vaccinations a crucial precaution. This trend is further bolstered by the growth of leisure travel, business travel, and international students studying abroad. Moreover, the desire for exotic and off-the-beaten-path travel experiences is leading individuals to explore regions with unique health risks, emphasizing the need for specialized vaccines. The growing awareness among individuals about health precautions while traveling is underscoring the importance of vaccines for international travelers, which is offering a favorable market outlook.
Government initiatives and regulations
Government initiatives and regulations play a pivotal role in driving the market. Many countries are recognizing the importance of safeguarding public health and preventing the spread of diseases through international travel. As a result, governing agencies of several countries are implementing stringent regulations and recommendations regarding travel vaccinations. These regulations often mandate certain vaccinations for travelers entering or exiting their borders, especially for destinations with known disease risks. The International Health Regulations (IHR) by the World Health Organization (WHO) require proof of yellow fever vaccination for travelers visiting certain countries. Additionally, some governments offer subsidized or free travel vaccinations to their citizens as part of public health programs. These regulations and initiatives not only create a legal requirement for travelers but also raise awareness about the necessity of travel vaccines, driving demand in the market.
Global disease outbreaks and pandemics
Global disease outbreaks and pandemics have a profound impact on driving the market. These events are encouraging travelers and governments, highlighting the potential health risks associated with international travel. In response to such outbreaks, there is an escalating demand for vaccines that can protect against specific infectious diseases prevalent in certain regions. Disease outbreaks and pandemics are leading to the development and distribution of vaccines to mitigate the spread of the virus and facilitate safe travel. Travelers are becoming more conscious about the need for vaccinations to protect themselves and others, leading to greater adoption of travel vaccines. Governments and international health organizations also emphasize the importance of vaccines as a key tool in preventing and controlling outbreaks, encouraging travelers to be vaccinated before embarking on their journeys.
Changing disease patterns and emerging threats
The dynamic nature of disease patterns and the emergence of new infectious threats are strengthening the growth of the market. Infectious diseases are not static, they evolve, mutate, and spread to new regions. This ever-changing landscape necessitates ongoing research and development (R&D) activities of vaccines to combat evolving pathogens. Diseases like Zika virus and Ebola are emerging as significant concerns for travelers in recent years, prompting the development of specific vaccines to address these threats. This awareness of changing disease patterns, along with the ease of accessing information, is encouraging individuals to seek protection through vaccinations before embarking on their journeys.
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global and regional levels for 2024-2032. Our report has categorized the market based on composition and disease.
Mono Vaccines
Combination Vaccines
Combination vaccines account for the majority of the market share
The report has provided a detailed breakup and analysis of the market based on the composition. This includes mono vaccines and combination vaccines. According to the report, combination vaccines represented the largest segment.
Combination vaccines offer the convenience of protecting against multiple diseases with a single injection. Popular combination vaccines include those that guard against hepatitis A and B, as well as typhoid. The primary advantage of combination vaccines is their efficiency in providing comprehensive protection, simplifying the vaccination process for travelers. This convenience is especially appealing to individuals who plan to visit regions with multiple disease risks, reducing the number of shots required. The combination vaccines segment is growing due to increased demand for streamlined vaccination regimens and improved compliance among travelers seeking a one-shot solution for their health needs.
Mono vaccines consist of individual vaccines targeting specific diseases. These vaccines are designed to provide protection against a single infectious agent, such as hepatitis A, hepatitis B, or typhoid. Mono vaccines are often recommended when travelers are visiting regions with a particularly high risk of one specific disease. They offer the advantage of targeted protection, allowing travelers to customize their vaccination regimen based on their destination and individual health needs.
Hepatitis A
DPT
Yellow Fever
Typhoid
Hepatitis B
Measles and Mumps
Rabies
Meningococcal
Varicella
Japanese Encephalitis
Others
Hepatitis A represents the leading market segment
The report has provided a detailed breakup and analysis of the market based on the disease. This includes hepatitis A, DPT, yellow fever, typhoid, hepatitis B, measles and mumps, rabies, meningococcal, varicella, Japanese encephalitis, and others. According to the report, hepatitis A represented the largest segment.
Hepatitis A is a highly contagious viral infection that can be contracted through contaminated food or water, making it a significant concern for travelers. This segment includes vaccines that provide immunity against the hepatitis A virus. Due to its prevalence in many travel destinations, hepatitis A vaccination is recommended for individuals traveling to regions with inadequate sanitation and hygiene standards. The prominence of hepatitis A in the market reflects the widespread recognition of its risk and the importance of vaccination for the health and safety of travelers.
DPT vaccines, which protect against diphtheria, pertussis (whooping cough), and tetanus, are another important segment in the travel vaccines market. While these diseases are not exclusive to travel-related risks, they are included in some international vaccination recommendations. Tetanus can be a concern if travelers are exposed to contaminated wounds during their journeys. Therefore, DPT vaccines are essential for ensuring comprehensive protection against these preventable diseases, even when traveling.
Yellow fever vaccines target the prevention of yellow fever, a mosquito-borne viral disease prevalent in certain tropical regions. Travelers visiting countries in Africa and South America where yellow fever is endemic often require proof of vaccination for entry. The yellow fever segment in the travel vaccines market serves travelers who plan to explore these high-risk areas and need to adhere to international health regulations.
Typhoid vaccines are essential for travelers heading to regions with a higher risk of typhoid fever, often linked to contaminated food and water sources. These vaccines protect against Salmonella typhi, the bacterium responsible for typhoid fever. The typhoid segment addresses the specific health needs of travelers venturing to areas with suboptimal sanitation and hygiene conditions.
Hepatitis B vaccines are important for travelers who may engage in activities that carry an elevated risk of exposure to the hepatitis B virus, such as unprotected sexual contact or medical procedures involving needles. While hepatitis B is not exclusive to travel, these vaccines cater to the needs of individuals seeking protection against this virus while away from their home country.
Asia Pacific
North America
Europe
Middle East and Africa
Latin America
North America leads the market, accounting for the largest travel vaccines market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America. According to the report, North America accounted for the largest market share due to the high level of outbound international travel from the United States and Canada. The region has a strong emphasis on health and safety during travel, and travelers are well-informed about the importance of vaccinations. Additionally, government recommendations and regulations, including those set by the Centers for Disease Control and Prevention (CDC) in the United States, play a significant role in promoting the uptake of travel vaccines. North America also benefits from a well-established healthcare infrastructure and a robust pharmaceutical industry, making travel vaccines readily accessible to the population.
Europe is another substantial market for travel vaccines. With its diverse range of destinations and a large number of international travelers, European countries have a strong demand for travel vaccinations. The European Union is establishing guidelines for travelers, recommending vaccinations based on destination and health history. European travelers tend to be proactive in seeking pre-travel healthcare advice, contributing to the growth of the market in the region.
The Asia Pacific region is experiencing rapid growth in the market due to a rise in outbound tourism and business travel. As economies in the region are expanding, more individuals have the means and desire to explore international destinations. This is resulting in a heightened awareness of travel-related health risks, catalyzing the demand for travel vaccines. Moreover, some countries are becoming popular tourist destinations, leading to an increase in inbound travelers who also require vaccinations.
The Middle East and Africa region also contribute to the market. This segment is driven by both outbound tourism and inbound travelers, as the region hosts various cultural, religious, and business events. Vaccinations are often mandated for individuals traveling to Mecca for Hajj or Umrah, further propelling the market growth. In addition, the presence of diseases like yellow fever and malaria underscores the importance of vaccinations for travelers.
Latin America is another growing market for travel vaccines, driven by increasing outbound travel from countries like Brazil and Mexico. Travelers from these regions often explore destinations within South America, North America, and Europe, necessitating vaccinations for disease prevention.
Key players in the market are actively engaged in several strategic initiatives. They are investing in research and development (R&D) activities to expand their vaccine portfolios, addressing emerging travel-related health risks and enhancing existing efficacy of vaccines. These companies are also focusing on increasing their global distribution networks to ensure accessibility to travel vaccines in diverse regions. Furthermore, they collaborate with healthcare providers, government agencies, and international health organizations to promote vaccination awareness and education among travelers. Additionally, pharmaceutical firms are exploring innovative vaccine delivery methods, such as oral or patch-based vaccines, to improve convenience and compliance for travelers. Overall, key players are dedicated to advancing the field of travel vaccines to meet the evolving needs of global travelers effectively.
GlaxoSmithKline Pharmaceuticals Limited
Sanofi Pasteur
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
ALK-Abello A/S
Bavarian Nordic A/S
Crucell (Subsidiary of Johnson & Johnson)
CSL Limited
AstraZeneca PLC
Altimmune, Inc.
Abbott Laboratories
Hoffmann-La Roche, Inc.
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
March 31, 2021: Sanofi Pasteur announced a huge investment in a new vaccine manufacturing facility at its existing site in Toronto, Canada. The investment in a new facility will provide additional antigen and filling capacity for Sanofi's Fluzone® High-Dose Quadrivalent influenza vaccine, helping to increase supply availability in Canada, the United States and Europe.
January 5, 2022: Pfizer Inc. and BioNTech SE announced a new research, development and commercialization collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles (herpes zoster virus, or HZV), a debilitating, disfiguring and painful disease that impacts about one in three people in the United States during their lifetime.
June 1, 2021: Merck & Co., Inc. announced that Vaxelis vaccine, developed as a part of a U.S. based partnership between Merck and Sanofi Pasteur is now available in the U.S. VAXELIS is the first and only hexavalent (six-in-one) combination vaccine available in the U.S. indicated for active immunization to help prevent diphtheria, tetanus, pertussis, poliomyelitis, and hepatitis B.